Deguelin Induces Both Apoptosis and Autophagy in Cultured Head and Neck Squamous Cell Carcinoma Cells

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Yang, Yan li ^a   Ji, Chao ^a   Bi, Zhi gang ^a   Lu, Chun cheng ^a   Wang, Rong ^a   Gu, Bing ^a   Cheng, Lei ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 9; CERAMIDE; CYCLIN DEPENDENT KINASE 4; DEGUELIN; FLUOROURACIL; HEAT SHOCK PROTEIN 90; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; PROTEIN BCL XL; PROTEIN KINASE; PROTEIN KINASE B; SODIUM CHLORIDE; SURVIVIN; SYNTHETASE; ULK1 KINASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER CELL CULTURE; CHEMOSENSITIZATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME DEGRADATION; ENZYME PHOSPHORYLATION; FEMALE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; INHIBITION KINETICS; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; AUTOPHAGY; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CERAMIDES; CYCLIN-DEPENDENT KINASE 4; FEMALE; FLUOROURACIL; HEAD AND NECK NEOPLASMS; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MICE; PROTO-ONCOGENE PROTEINS C-AKT; ROTENONE; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS MUSCULUS;

EID: 84872772327     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0054736     Document Type: Article

References (67)

1. Stell PM, (1989) Survival times in end-stage head and neck cancer. Eur J Surg Oncol 15: 407-410.
2. Aggarwal S, Takada Y, Singh S, Myers JN, Aggarwal BB, (2004) Inhibition of growth and survival of human head and neck squamous cell carcinoma cells by curcumin via modulation of nuclear factor-kappaB signaling. Int J Cancer 111: 679-692.
3. Stell PM, (1991) Time to recurrence of squamous cell carcinoma of the head and neck. Head Neck 13: 277-281.
4. Bozec A, Peyrade F, Fischel JL, Milano G, (2009) Emerging molecular targeted therapies in the treatment of head and neck cancer. Expert Opin Emerg Drugs 14: 299-310.
5. Goerner M, Seiwert TY, Sudhoff H, (2010) Molecular targeted therapies in head and neck cancer-an update of recent developments. Head Neck Oncol 2: 8.
6. Sano D, Fooshee DR, Zhao M, Andrews GA, Frederick MJ, et al. (2011) Targeted molecular therapy of head and neck squamous cell carcinoma with the tyrosine kinase inhibitor vandetanib in a mouse model. Head Neck 33: 349-358.
7. Lee HY, Oh SH, Woo JK, Kim WY, Van Pelt CS, et al. (2005) Chemopreventive effects of deguelin, a novel Akt inhibitor, on tobacco-induced lung tumorigenesis. J Natl Cancer Inst 97: 1695-1699.
8. Murillo G, Kosmeder JW 2nd, Pezzuto JM, Mehta RG (2003) Deguelin suppresses the formation of carcinogen-induced aberrant crypt foci in the colon of CF-1 mice. Int J Cancer 104: 7-11.
9. Udeani GO, Gerhauser C, Thomas CF, Moon RC, Kosmeder JW, et al. (1997) Cancer chemopreventive activity mediated by deguelin, a naturally occurring rotenoid. Cancer Res 57: 3424-3428.
10. Gerhauser C, Mar W, Lee SK, Suh N, Luo Y, et al. (1995) Rotenoids mediate potent cancer chemopreventive activity through transcriptional regulation of ornithine decarboxylase. Nat Med 1: 260-266.
11. Bortul R, Tazzari PL, Billi AM, Tabellini G, Mantovani I, et al. (2005) Deguelin, A PI3K/AKT inhibitor, enhances chemosensitivity of leukaemia cells with an active PI3K/AKT pathway. Br J Haematol 129: 677-686.
12. Tripathi Bhar A, Banerjee S, Chunder N, Roy A, Sengupta A, et al. (2003) Differential alterations of the genes in the CDKN2A-CCND1-CDK4-RB1 pathway are associated with the development of head and neck squamous cell carcinoma in Indian patients. J Cancer Res Clin Oncol 129: 642-650.
13. Nair AS, Shishodia S, Ahn KS, Kunnumakkara AB, Sethi G, et al. (2006) Deguelin, an Akt inhibitor, suppresses IkappaBalpha kinase activation leading to suppression of NF-kappaB-regulated gene expression, potentiation of apoptosis, and inhibition of cellular invasion. J Immunol 177: 5612-5622.
14. Peng XH, Karna P, O'Regan RM, Liu X, Naithani R, et al. (2007) Down-regulation of inhibitor of apoptosis proteins by deguelin selectively induces apoptosis in breast cancer cells. Mol Pharmacol 71: 101-111.
15. Oh SH, Woo JK, Yazici YD, Myers JN, Kim WY, et al. (2007) Structural basis for depletion of heat shock protein 90 client proteins by deguelin. J Natl Cancer Inst 99: 949-961.
16. Ji C, Yang B, Yang YL, He SH, Miao DS, et al. (2010) Exogenous cell-permeable C6 ceramide sensitizes multiple cancer cell lines to Doxorubicin-induced apoptosis by promoting AMPK activation and mTORC1 inhibition. Oncogene 29: 6557-6568.
17. Ji C, Yang Y, Yang B, Xia J, Sun W, et al. (2010) Trans-Zeatin attenuates ultraviolet induced down-regulation of aquaporin-3 in cultured human skin keratinocytes. Int J Mol Med 26: 257-263.
18. Zhu QY, Wang Z, Ji C, Cheng L, Yang YL, et al. (2011) C6-ceramide synergistically potentiates the anti-tumor effects of histone deacetylase inhibitors via AKT dephosphorylation and alpha-tubulin hyperacetylation both in vitro and in vivo. Cell Death Dis 2: e117.
19. Ji C, Yang YL, He L, Gu B, Xia JP, et al. (2012) Increasing ceramides sensitizes genistein-induced melanoma cell apoptosis and growth inhibition. Biochem Biophys Res Commun 421: 462-467.
20. Ji C, Yang YL, Yang Z, Tu Y, Cheng L, et al. (2012) Perifosine sensitizes UVB-induced apoptosis in skin cells: new implication of skin cancer prevention? Cell Signal 24: 1781-1789.
21. Veldman RJ, Klappe K, Hoekstra D, Kok JW, (1998) Metabolism and apoptotic properties of elevated ceramide in HT29rev cells. Biochem J 331 (Pt 2): 563-569.
22. Sommer K, Peters SO, Robins IH, Raap M, Wiedemann GJ, et al. (2001) A preclinical model for experimental chemotherapy of human head and neck cancer. Int J Oncol 18: 1145-1149.
23. Bruzzese F, Di Gennaro E, Avallone A, Pepe S, Arra C, et al. (2006) Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN-alpha in head and neck cancer cells in vitro and in vivo. Clin Cancer Res 12: 617-625.
24. Freudlsperger C, Burnett JR, Friedman JA, Kannabiran VR, Chen Z, et al. (2011) EGFR-PI3K-AKT-mTOR signaling in head and neck squamous cell carcinomas: attractive targets for molecular-oriented therapy. Expert Opin Ther Targets 15: 63-74.
25. Sato S, Fujita N, Tsuruo T, (2000) Modulation of Akt kinase activity by binding to Hsp90. Proc Natl Acad Sci U S A 97: 10832-10837.
26. Fortugno P, Beltrami E, Plescia J, Fontana J, Pradhan D, et al. (2003) Regulation of survivin function by Hsp90. Proc Natl Acad Sci U S A 100: 13791-13796.
27. Vaughan CK, Gohlke U, Sobott F, Good VM, Ali MM, et al. (2006) Structure of an Hsp90-Cdc37-Cdk4 complex. Mol Cell 23: 697-707.
28. Stepanova L, Leng X, Parker SB, Harper JW, (1996) Mammalian p50Cdc37 is a protein kinase-targeting subunit of Hsp90 that binds and stabilizes Cdk4. Genes Dev 10: 1491-1502.
29. Kabakov AE, Kudryavtsev VA, Gabai VL, (2010) Hsp90 inhibitors as promising agents for radiotherapy. J Mol Med (Berl) 88: 241-247.
30. Reynolds CP, Maurer BJ, Kolesnick RN, (2004) Ceramide synthesis and metabolism as a target for cancer therapy. Cancer Lett 206: 169-180.
31. Bose R, Verheij M, Haimovitz-Friedman A, Scotto K, Fuks Z, et al. (1995) Ceramide synthase mediates daunorubicin-induced apoptosis: an alternative mechanism for generating death signals. Cell 82: 405-414.
32. Kolesnick RN, Kronke M, (1998) Regulation of ceramide production and apoptosis. Annu Rev Physiol 60: 643-665.
33. Merrill AH Jr, van Echten G, Wang E, Sandhoff K, (1993) Fumonisin B1 inhibits sphingosine (sphinganine) N-acyltransferase and de novo sphingolipid biosynthesis in cultured neurons in situ. J Biol Chem 268: 27299-27306.
34. Charles AG, Han TY, Liu YY, Hansen N, Giuliano AE, et al. (2001) Taxol-induced ceramide generation and apoptosis in human breast cancer cells. Cancer Chemother Pharmacol 47: 444-450.
35. Egan D, Kim J, Shaw RJ, Guan KL, (2011) The autophagy initiating kinase ULK1 is regulated via opposing phosphorylation by AMPK and mTOR. Autophagy 7: 643-644.
36. Roach PJ, (2011) AMPK-> ULK1-> autophagy. Mol Cell Biol 31: 3082-3084.
37. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, et al. (2003) Cancer statistics, 2003. CA Cancer J Clin 53: 5-26.
38. LoTempio MM, Veena MS, Steele HL, Ramamurthy B, Ramalingam TS, et al. (2005) Curcumin suppresses growth of head and neck squamous cell carcinoma. Clin Cancer Res 11: 6994-7002.
39. Simmonds MA, (2003) Cancer statistics, 2003: further decrease in mortality rate, increase in persons living with cancer. CA Cancer J Clin 53: 4.
40. Brockstein B, Haraf DJ, Rademaker AW, Kies MS, Stenson KM, et al. (2004) Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience. Ann Oncol 15: 1179-1186.
41. Katschinski DM, Le L, Heinrich D, Wagner KF, Hofer T, et al. (2002) Heat induction of the unphosphorylated form of hypoxia-inducible factor-1alpha is dependent on heat shock protein-90 activity. J Biol Chem 277: 9262-9267.
42. Isaacs JS, Jung YJ, Mimnaugh EG, Martinez A, Cuttitta F, et al. (2002) Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway. J Biol Chem 277: 29936-29944.
43. Peng Y, Chen L, Li C, Lu W, Chen J, (2001) Inhibition of MDM2 by hsp90 contributes to mutant p53 stabilization. J Biol Chem 276: 40583-40590.
44. Wang C, Chen J, (2003) Phosphorylation and hsp90 binding mediate heat shock stabilization of p53. J Biol Chem 278: 2066-2071.
45. Moral M, Paramio JM, (2008) Akt pathway as a target for therapeutic intervention in HNSCC. Histol Histopathol 23: 1269-1278.
46. Lippert BM, Knauer SK, Fetz V, Mann W, Stauber RH, (2007) Dynamic survivin in head and neck cancer: molecular mechanism and therapeutic potential. Int J Cancer 121: 1169-1174.
47. Rosenfeldt MT, Ryan KM, (2011) The multiple roles of autophagy in cancer. Carcinogenesis 32: 955-963.
48. Lee JH, Jang JT, Choi JS, Moon SH, Noh SH, et al. (2011) Exchange-coupled magnetic nanoparticles for efficient heat induction. Nat Nanotechnol 6: 418-422.
49. Lee JW, Park S, Takahashi Y, Wang HG, (2011) The association of AMPK with ULK1 regulates autophagy. PLoS One 5: e15394.
50. Mihaylova MM, Shaw RJ, (2011) The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nat Cell Biol 13: 1016-1023.
51. Yao C, Wei JJ, Wang ZY, Ding HM, Li D, et al. (2012) Perifosine Induces Cell Apoptosis in Human Osteosarcoma Cells: New Implication for Osteosarcoma Therapy? Cell Biochem Biophys.
52. Sun H, Yu T, Li J, (2011) Co-administration of perifosine with paclitaxel synergistically induces apoptosis in ovarian cancer cells: more than just AKT inhibition. Cancer Lett 310: 118-128.
53. Gills JJ, Dennis PA, (2009) Perifosine: update on a novel Akt inhibitor. Curr Oncol Rep 11: 102-110.
54. Ji C, Yang YL, He L, Gu B, Xia JP, et al. (2012) Increasing ceramides sensitizes genistein-induced melanoma cell apoptosis and growth inhibition. Biochem Biophys Res Commun.
55. Chen MB, Shen WX, Yang Y, Wu XY, Gu JH, et al. (2011) Activation of AMP-activated protein kinase is involved in vincristine-induced cell apoptosis in B16 melanoma cell. J Cell Physiol 226: 1915-1925.
56. Chen MB, Wu XY, Gu JH, Guo QT, Shen WX, et al. (2010) Activation of AMP-activated protein kinase contributes to doxorubicin-induced cell death and apoptosis in cultured myocardial H9c2 cells. Cell Biochem Biophys 60: 311-322.
57. Rocha GZ, Dias MM, Ropelle ER, Osorio-Costa F, Rossato FA, et al. (2011) Metformin amplifies chemotherapy-induced AMPK activation and antitumoral growth. Clin Cancer Res 17: 3993-4005.
58. Zhang WB, Wang Z, Shu F, Jin YH, Liu HY, et al. (2010) Activation of AMP-activated protein kinase by temozolomide contributes to apoptosis in glioblastoma cells via p53 activation and mTORC1 inhibition. J Biol Chem 285: 40461-40471.
59. Chen MB, Wu XY, Gu JH, Guo QT, Shen WX, et al. (2011) Activation of AMP-activated protein kinase contributes to doxorubicin-induced cell death and apoptosis in cultured myocardial H9c2 cells. Cell Biochem Biophys 60: 311-322.
60. Zheng QY, Jin FS, Yao C, Zhang T, Zhang GH, et al. (2012) Ursolic acid-induced AMP-activated protein kinase (AMPK) activation contributes to growth inhibition and apoptosis in human bladder cancer T24 cells. Biochem Biophys Res Commun 419: 741-747.
61. Nagalingam A, Arbiser JL, Bonner MY, Saxena NK, Sharma D, (2012) Honokiol activates AMP-activated protein kinase in breast cancer cells via an LKB1-dependent pathway and inhibits breast carcinogenesis. Breast Cancer Res 14: R35.
62. Kang MR, Park SK, Lee CW, Cho IJ, Jo YN, et al. (2012) Widdrol induces apoptosis via activation of AMP-activated protein kinase in colon cancer cells. Oncol Rep 27: 1407-1412.
63. Hwang JT, Ha J, Park IJ, Lee SK, Baik HW, et al. (2007) Apoptotic effect of EGCG in HT-29 colon cancer cells via AMPK signal pathway. Cancer Lett 247: 115-121.
64. Lee YK, Hwang JT, Kwon DY, Surh YJ, Park OJ, (2010) Induction of apoptosis by quercetin is mediated through AMPKalpha1/ASK1/p38 pathway. Cancer Lett 292: 228-236.
65. Jang KY, Jeong SJ, Kim SH, Jung JH, Kim JH, et al. (2012) Activation of reactive oxygen species/AMP activated protein kinase signaling mediates fisetin-induced apoptosis in multiple myeloma U266 cells. Cancer Lett.
66. Din FV, Valanciute A, Houde VP, Zibrova D, Green KA, et al. (2012) Aspirin inhibits mTOR signaling, activates AMP-activated protein kinase, and induces autophagy in colorectal cancer cells. Gastroenterology 142: 1504-1515 e1503.
67. Liu YQ, Cheng X, Guo LX, Mao C, Chen YJ, et al. (2012) Identification of an Annonaceous Acetogenin Mimetic, AA005, as an AMPK Activator and Autophagy Inducer in Colon Cancer Cells. PLoS One 7: e47049.